Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation
Eon Ju Jeon (Jeon EJ), Eui Dal Jung (Jung ED)
Endocrinol Metab. 2014;29(1):33-39.   Published online 2014 Mar 14     DOI: https://doi.org/10.3803/EnM.2014.29.1.33
Citations to this article as recorded by Crossref logo
Long-Term Prognostic Value of the Response to Therapy Assessed by Laboratory and Imaging Findings in Patients with Differentiated Thyroid Cancer
Michele Klain, Emilia Zampella, Leandra Piscopo, Fabio Volpe, Mariarosaria Manganelli, Stefania Masone, Leonardo Pace, Domenico Salvatore, Martin Schlumberger, Alberto Cuocolo
Cancers.2021; 13(17): 4338.     CrossRef
Lack of Efficacy of Radioiodine Remnant Ablation for Papillary Thyroid Microcarcinoma: Verification Using Inverse Probability of Treatment Weighting
Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Suyeon Park, Mijin Kim, Tae Yong Kim, Minkyu Han, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim
Annals of Surgical Oncology.2017; 24(9): 2596.     CrossRef
Evaluation of 131I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients
Jose Manuel Gonzalez Carvalho, Dennis Görlich, Otmar Schober, Christian Wenning, Burkhard Riemann, Frederik Anton Verburg, Alexis Vrachimis
European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(5): 744.     CrossRef
Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial
Yuan Qu, Rui Huang, Lin Li
Annals of Nuclear Medicine.2017; 31(1): 71.     CrossRef
ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach
Livia Lamartina, Désirée Deandreis, Cosimo Durante, Sebastiano Filetti
European Journal of Endocrinology.2016; 175(5): R185.     CrossRef
The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative131I dose over 37 GBq
Ah Reum Khang, Sun Wook Cho, Hoon Sung Choi, Hwa Young Ahn, Won Sang Yoo, Kyung Won Kim, Keon Wook Kang, Ka Hee Yi, Do Joon Park, Dong Soon Lee, June-Key Chung, Bo Youn Cho, Young Joo Park
Clinical Endocrinology.2015; 83(1): 117.     CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
Recent Changes in the Clinical Outcome of Papillary Thyroid Carcinoma With Cervical Lymph Node Metastasis
Min Ji Jeon, Won Gu Kim, Yun Mi Choi, Hyemi Kwon, Dong Eun Song, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Ki-Wook Chung, Won Bae Kim
The Journal of Clinical Endocrinology & Metabolism.2015; 100(9): 3470.     CrossRef
Letter: Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation (Endocrinol Metab 2014;29:33-9, Eon Ju Jeon et al.)
Chan-Hee Jung
Endocrinology and Metabolism.2014; 29(2): 206.     CrossRef